Imago BioSciences to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference

Rhea-AI Summary

Imago BioSciences (Nasdaq: IMGO) announced that CEO Hugh Y. Rienhoff, Jr., M.D., will participate in a fireside chat at the Guggenheim Healthcare Talks 2022 Oncology Conference on February 10, 2022, at 10:30 a.m. PT / 1:30 p.m. ET. The live audio webcast can be accessed via the Investor Relations section of the company's website, with a replay available for 90 days post-event.

Imago is focused on developing novel therapies for myeloproliferative neoplasms (MPNs), with their lead product, Bomedemstat, currently in Phase 2 trials.

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that Hugh Y. Rienhoff, Jr., M.D., Imago’s Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 2022 Oncology Conference on Thursday, February 10, 2022 at 10:30 a.m. PT / 1:30 p.m. ET.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.imagobio.com. The webcast replay will be available after the conclusion of the fireside chat for approximately 90 days.

About Imago BioSciences

Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. Imago is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (NCT04254978) and myelofibrosis (NCT03136185). Bomedemstat has U.S. FDA Orphan Drug and Fast Track Designation for the treatment of ET and MF, European Medicines Agency (EMA) Orphan Designation for the treatment of ET and MF, and PRIority MEdicines (PRIME) Designation by the EMA for the treatment of MF. The company is based in South San Francisco, California. To learn more, visit www.imagobio.com, www.myelofibrosisclinicalstudy.com, www.etclinicalstudy.com and follow us on Twitter @ImagoBioRx, Facebook and LinkedIn.

Contacts

INVESTORS
Laurence Watts
Gilmartin Group, LLC.
laurence@gilmartinir.com

MEDIA
Will Zasadny
Canale Communications
will.zasadny@canalecomm.com

FAQ

What is the date and time of Imago BioSciences' fireside chat at the Guggenheim Healthcare Talks 2022?

The fireside chat will take place on February 10, 2022, at 10:30 a.m. PT / 1:30 p.m. ET.

How can I listen to the Imago BioSciences fireside chat?

You can access the live audio webcast from the Investor Relations section of Imago's website.

What is the focus of Imago BioSciences?

Imago BioSciences is focused on discovering and developing new treatments for myeloproliferative neoplasms (MPNs).

What product candidate is Imago BioSciences currently developing?

Imago's lead product candidate is Bomedemstat, which targets lysine-specific demethylase 1 (LSD1).

What are the ongoing clinical trials for Bomedemstat?

Bomedemstat is being evaluated in two Phase 2 clinical trials for essential thrombocythemia and myelofibrosis.

What designations has Bomedemstat received from regulatory authorities?

Bomedemstat has received U.S. FDA Orphan Drug and Fast Track Designation, as well as EMA Orphan Designation.